Perfusion CT: Noninvasive Surrogate Marker for Stratification of Pancreatic Cancer Response to Concurrent Chemo- and Radiation Therapy
Authors:
- Mi-Suk ParkMPMi-Suk Park
- Ernst KlotzEKErnst Klotz
- Myeong-Jin KimMKMyeong-Jin Kim
- Si Young SongSSSi Young Song
- Seung Woo ParkSPSeung Woo Park
- Seung-Whan ChaSCSeung-Whan Cha
- Joon Soek LimJLJoon Soek Lim
- Jinsil SeongJSJinsil Seong
- Jae Bok ChungJCJae Bok Chung
- Ki Whang KimKKKi Whang Kim
- 1 January 2009
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 250 (1) , 110-117
Abstract
To prospectively determine whether perfusion computed tomography (CT) parameters, such as volume transfer constant (K(trans)) between blood plasma and extracellular extravascular space (EES) and blood volume calculated from dynamic CT data, can be used to predict response of pancreatic cancer to concurrent chemotherapy and radiation therapy (CCRT). This prospective study was institutional review board approved, and written informed consent was obtained. Thirty patients with pancreatic cancer underwent perfusion CT with 64-detector row CT before gemcitabine-based CCRT. Two perfusion parameters (K(trans) and blood volume) measured before treatment were compared between patients who responded to treatment and those who did not, as determined with World Health Organization criteria from first and second posttherapeutic follow-up CT examinations, which were performed at 3- and 6-month follow-up. Statistical analysis was performed with the two-sample t test. A receiver operating characteristic curve was used to determine the best cutoff value of perfusion parameters for differentiation of responders from nonresponders. Twenty of 30 patients examined at 3-month follow-up responded to therapy. Their pretreatment K(trans) value was significantly higher than that of nonresponders (50.8 mL/100 mL/min +/- 30.5 [standard deviation] vs 19.0 mL/100 mL/min +/- 10.8, P = .001). The best cutoff value for differentiating between responders and nonresponders was 31.8 mL/100 mL/min, which yielded 75.0% sensitivity and 90.0% specificity. Ten of 18 patients examined at 6-month follow-up responded to therapy. Their pretreatment K(trans) value was significantly higher than that of nonresponders (58.6 mL/100 mL/min +/- 43.2 vs 19.8 mL/100 mL/min +/- 10.9, P = .002). Responders also had higher blood volume values, but this difference was not significant. Tumors with a high pretreatment K(trans) value tended to respond better to CCRT than did tumors with a low pretreatment K(trans) value. Perfusion CT may be used to predict tumor response to CCRT in patients with pancreatic cancer. This might aid in development of a tailored approach to therapy in these patients.Keywords
This publication has 28 references indexed in Scilit:
- Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative TherapyAnnals of Surgical Oncology, 2006
- Locally Advanced Pancreatic CancerJournal of Clinical Oncology, 2005
- Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III TrialJournal of Clinical Oncology, 2005
- Assessing Tumor Perfusion and Treatment Response in Rectal Cancer with Multisection CT: Initial ObservationsRadiology, 2005
- Perfusion Imaging of the Liver: Current Challenges and Future GoalsRadiology, 2005
- Functional CT imaging in oncologyEuropean Radiology, 2003
- Perfusion CT for the assessment of tumour vascularity: which protocol?British Journal of Radiology, 2003
- Perfusion CT: a worthwhile enhancement?British Journal of Radiology, 2003
- Functional computed tomography in oncologyEuropean Journal of Cancer, 2002
- Early Changes in Liver Perfusion Caused by Occult Metastases in Rats: Detection with Quantitative CTRadiology, 2001